期刊文献+

肿瘤免疫治疗与化疗的协同效应研究现状 被引量:2

下载PDF
导出
摘要 肿瘤免疫治疗由于其较低的毒性和较高的特异性,长期以来一直被认为是一种很有吸引力的治疗手段,其中肿瘤抗原特异性细胞毒性T细胞(CTL)是最为理想的免疫效应细胞。肿瘤免疫治疗主要包括细胞因子、单克隆抗体、肿瘤疫苗及细胞过继免疫治疗等。实体肿瘤免疫主要通过CTL、自然杀伤细胞(NK)、自然杀伤T细胞(NKT)等介导杀伤效应。树突细胞(DCs)在协调上述细胞的过程中扮演重要角色。而肿瘤相关巨噬细胞(TAM)、调节性T细胞(Treg)、骨髓来源的抑制性细胞(MDSC)又形成了一个抑制免疫效应的网络,在免疫抑制因素存在时如何有效诱导抗肿瘤T细胞效应一直备受关注。
作者 黄纯 李凯
出处 《天津医科大学学报》 2015年第4期363-366,共4页 Journal of Tianjin Medical University
基金 国家自然科学基金面上资助项目(81372467)
  • 相关文献

参考文献37

  • 1Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age[J]. Nature, 2011,480(7378): 480.
  • 2Liao T, Kaufmann A M, Qian X, et al. Susceptibility to cytotoxic T cell lysis of Cancer stem cells derived from cervical and head and neck tumor cell lines[J]. J Cancer Res Clin Oncol, 2013, 139(1): 159.
  • 3Behl D, Porrata L F, Markovic S N, et al. Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia[J]. Leukemia, 2005, 23(16, 1, S): 573S.
  • 4Schmidt T L, Negrin R S, Contag C H. A killer choice for Cancer immunotherapy[J]. Immunol Res, 2014, 58(2/3): 300.
  • 5Lake R A, Robinson B W. Immunotherapy and chemotherapy-a practical partnership[J]. Nat Rev Cancer, 2005, 5(5): 397.
  • 6Ramakrishnan R I, Gabrilovich D I. Mechanism of synergistic effect of chemotherapy and immunotherapy of cancer [J]. Cancer Immunol Immunother, 2011, 60(3): 419.
  • 7Liseth K, Ersvaer E, Hervig T, et al. Combination of intensive chemotherapy and anticanccr vaccines in the treatment of human malignancies: the hematological experience[J]. J Biomed Biotechnol, 2010,2010:692097.
  • 8Spisek R, Charalambous A, Mazumder A, et al. Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells:therapeutic implications[J]. Blood, 2007, 109(11): 4839.
  • 9Jensen H, Andresen L, Hansen K A, et al. Cell-surface expression of HspT0 on hematopoietic cancer cells after inhibition of HDAC activity[J]. J Leukoc Biol, 2009, 86(4): 923.
  • 10Shurin G V, Tourkova I L, Kaneno R, et al. Chemotherapeutic agents in noneytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-Dependent mechanism[J]. J Immunol, 2009, 183(1): 137.

同被引文献40

  • 1Mellman I, Coukos G; Dranoff G. Cancer immunotherapy comes of age. Nature, 2011,480(7378):480-489.
  • 2Chakrabarty AM. Microorganisms and cancer: quest for a therapy. J Bacteriol, 2003, 185(9):2683-2686.
  • 3Behl D, Porrata LF, Markovic SN, et al. Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia. Leukemia, 2006, 20(1):29-34.
  • 4Jain V, Jain S, Mahajan SC. Nanomedicines based drug delivery systems for anti-cancer targeting and treatment. Curr Drug Deliv, 2015 12(2):177-191.
  • 5Carney RP, Astier Y, Carney TM, et al. Electrical method to quantify nanoparticle interaction with lipid bilayers. ACS Nano, 2013, 7(2): 932-942.
  • 6Ellebaek E, Andersen MH, Svane IM, et al. Immunotherapy for metastatic colorectal cancer: present status and new options. Scand J Gastroenterol, 2012, 47(3):315-324.
  • 7Shurin MR, Naiditch H, Zhong H, et al. Regulatory dendritic cells: new targets for cancer immunotherapy. Cancer Biol Ther, 2011, 11 (11) 988-992.
  • 8Sabado RL, Bhardwaj N. Dendritic cell immunotherapy. Ann N Y Acad Sci, 2013, 1284:31-45.
  • 9Clifton GT, Sears AK, Clive KS, et al. Folate receptor alpha: a storied past and promising future in immunotherapy. Hum Vaccin, 2011, 7(2): 183-190.
  • 10Guo Y, Wang D, Song Q, et al. Erythrocyte membrane-enveloped polymeric nanopartieles as nanovaccine for induction of antitumor immunity against melanoma. ACS Nano, 2015, 9(7):6918-6933.

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部